1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsBrightFocus Foundation Research Grants is sponsored by BrightFocus Foundation. Awards grants for research on Alzheimer's, macular degeneration, and glaucoma, including basic, translational, and clinical studies.
Get alerted about grants like this
Save a search for “BrightFocus Foundation” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Apply for a Research Grant | BrightFocus Foundation Apply for a Research Grant BrightFocus provides research funds for U.S. domestic as well as international researchers pursuing pioneering research leading to greater understanding, prevention, and treatment of Alzheimer’s disease, macular degeneration, and glaucoma.
Alzheimer’s Disease Research Request for Proposals → Macular Degeneration Research Request for Proposals → National Glaucoma Research Request for Proposals → To start a new application and upload attachments, you must use our ProposalCentral application portal to apply online. Note: Your organization must be registered with ProposalCentral to apply.
Macular Degeneration Research grant recipient, Yong-Su Kwon, PhD It is our firm belief that having the courage to invest in innovative ideas will lead to revolutionary therapies. BrightFocus provides initial funding for highly innovative experimental ideas, including interdisciplinary investigations that may apply to two or three of the BrightFocus disease interests.
Most of the awardees use the BrightFocus award funds to demonstrate key findings that lead to later interest and additional funding from industrial or governmental funding agencies. Grant Application Resources Frequently Asked Questions Get answers to applicants’ frequently asked questions, from eligibility to the review process, categorized by each disease program.
From file type and size to formatting requirements, ensure your application checks the necessary boxes. Your guide to understanding the conditions of funding and the definitions and abbreviations used throughout the grant agreement. National Glaucoma Research-funded scientist Ignacio Provencio, PhD.
Recent News & Breakthroughs Browse research news and breakthroughs from BrightFocus-funded scientists.
BrightFocus Foundation Announces President and CEO Planned Retirement and Launches National Search BrightFocus Foundation today announced that Stacy Pagos Haller has shared her intention to retire as president and chief executive officer following the successful completion of a national search and the appointment of a successor, after 16 years of leadership.
Understanding the Causes of Steroid-Induced Glaucoma A commonly used medication is linked to increased risk of glaucoma. A BrightFocus National Glaucoma Research-funded scientist is trying to understand why. Can Better Sleep Slow Alzheimer’s?
New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way.
Dr. David Abramson Receives 2026 Helen Keller Prize for Vision Research from BrightFocus Foundation and Helen Keller Foundation A pioneering clinician-scientist at Memorial Sloan Kettering Cancer Center, Dr. Abramson has transformed understanding and treatment of eye cancers worldwide.
FDA Approves Repurposed Anti-Depressant to Treat Alzheimer’s-Associated Agitation Auvelity, developed by Axsome Therapeutics, was approved today by the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease agitation, a common and challenging symptom that affects 40 to 60 percent of people living with Alzheimer’s.
BrightFocus Honors 5 Vision Scientists Advancing Breakthrough Eye Research At a ceremony recognizing 2026 vision grant recipients, these prestigious awards honor five standout scientists whose work is shaping the future of prevention, treatments, and cures for macular degeneration and glaucoma—two leading causes of vision loss.
Donor Support Powers $16M+ Investment in 69 Projects Tackling Alzheimer’s, Macular Degeneration, and Glaucoma Following a year of uncertainty surrounding federal biomedical research funding, BrightFocus Foundation provides critical support for innovative brain and eye research.
Breaking News Dispatch: Alzheimer’s Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge Get the latest research news from the 2026 International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference.
Focusing on the Future: Key Takeaways from the 2025 Glaucoma Fast Track BrightFocus Foundation’s 2025 Glaucoma Fast Track brought together early-career and established scientists to provide a thorough overview of the biology, diagnosis, and treatment of glaucoma.
BrightFocus Foundation Announces President and CEO Planned Retirement and Launches National Search BrightFocus Foundation today announced that Stacy Pagos Haller has shared her intention to retire as president and chief executive officer following the successful completion of a national search and the appointment of a successor, after 16 years of leadership.
Understanding the Causes of Steroid-Induced Glaucoma A commonly used medication is linked to increased risk of glaucoma. A BrightFocus National Glaucoma Research-funded scientist is trying to understand why. Can Better Sleep Slow Alzheimer’s?
New BrightFocus-funded research suggests restoring sleep may help protect the brain from dementia progression, and a common insomnia drug could help lead the way.
Dr. David Abramson Receives 2026 Helen Keller Prize for Vision Research from BrightFocus Foundation and Helen Keller Foundation A pioneering clinician-scientist at Memorial Sloan Kettering Cancer Center, Dr. Abramson has transformed understanding and treatment of eye cancers worldwide.
FDA Approves Repurposed Anti-Depressant to Treat Alzheimer’s-Associated Agitation Auvelity, developed by Axsome Therapeutics, was approved today by the U.S. Food & Drug Administration (FDA) for the treatment of Alzheimer’s disease agitation, a common and challenging symptom that affects 40 to 60 percent of people living with Alzheimer’s.
BrightFocus Honors 5 Vision Scientists Advancing Breakthrough Eye Research At a ceremony recognizing 2026 vision grant recipients, these prestigious awards honor five standout scientists whose work is shaping the future of prevention, treatments, and cures for macular degeneration and glaucoma—two leading causes of vision loss.
Donor Support Powers $16M+ Investment in 69 Projects Tackling Alzheimer’s, Macular Degeneration, and Glaucoma Following a year of uncertainty surrounding federal biomedical research funding, BrightFocus Foundation provides critical support for innovative brain and eye research.
Breaking News Dispatch: Alzheimer’s Oral Therapies, Prevention Strategies, and Targeted Treatments Emerge Get the latest research news from the 2026 International Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) conference.
Focusing on the Future: Key Takeaways from the 2025 Glaucoma Fast Track BrightFocus Foundation’s 2025 Glaucoma Fast Track brought together early-career and established scientists to provide a thorough overview of the biology, diagnosis, and treatment of glaucoma.
Based on current listing details, eligibility includes: Researchers worldwide. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Research Project Grant (R01) is sponsored by National Institutes of Health (NIH). The NIH R01 grant is a widely used mechanism to provide substantial support for health-related research projects. While not exclusively for social work, social work faculty and doctoral students (often as part of a research team) can apply for R01 funding for projects exploring the linkages between education and health, or social work practice and health outcomes.
Small Research Grant Program (R03) is sponsored by National Institutes of Health (NIH). The NIH R03 grant supports small, time-limited research projects, which can include dissertation research. This grant mechanism is suitable for social work scholars conducting pilot studies, developing new methodologies, or performing secondary data analysis relevant to NIH's public health goals.